Shenzhou Cell (688520): Eight factor dosage turned a loss into a profit in 24Q1
Shenzhou Cell (688520): Continued rapid release of recombinant eight factors helps the company to turn losses into profits
Shenzhou Cell (688520): Recombinant factor VIII continues to grow at a high level, and annual results are expected to continue to be released
Shenzhou Cell (688520): 1Q24 net profit reverses loss; focus on the progress of the Eight Factor overseas listing
Shenzhou Cell (688520): R&D pipeline for rapid release of recombinant factor VIII continues to be rich
Huafu Securities released a research report on April 18 stating that it gave Shenzhou Cell (688520.SH) a purchase rating, and the target price was 62.84 yuan. The main reasons for the rating include: 1) the product matrix is beginning to take shape, and i
Shenzhou Cell (688520): Continued high growth on the revenue side, turning losses into inflection points
SDIC Securities released a research report on April 16 stating that it gave Shenzhou Cell (688520.SH) a purchase rating and the target price was 51.06 yuan. The main reasons for the rating include: 1) the company's gross margin increased slightly in 2023,
Shenzhou Cell (688520): The matrix of recombinant eight-factor rapid release commercial products is gradually being enriched
Shenzhou Cell-U (688520): Eight recombinant factors, high growth, focus on the company's commercialization progress
Shenzhou Cell (688520): High quality and low cost dual-drive biopharmaceutical industrialization platform
Shenzhou Cell (688520) depth: it has a biopharmaceutical+vaccine dual platform recombinant eight factor competitive advantage
Shenzhou Cell-U (688520): The recombinant eight-factor high-growth innovation pipeline enters the harvest season
Shenzhou Cell (688520): Product strength continues in 2023, revenue will increase by 80% to nearly 1.9 billion yuan
Shenzhou Cell (688520) Company Information Update Report: The company plans to increase the number of actual controllers by no more than 900 million yuan to further enhance the company's competitiveness
Shenzhou Cell (688520): Real Controllers Increase Company's Asset Optimization Confidence by 900 Million Yuan
Shenzhou Cell (688520): The new PD-1 vaccine for head and neck squamous cell carcinoma has been approved and its strength has been re-verified
Shenzhou Cell-U (688520): recombinant eight factors, continuous volume, multiple pipeline layout to drive future development
Shenzhou Cell (688520) 2023 Third Quarter Report Review: Single Q3 Revenue Increased 19.2% Month-on-Month, Reorganization Eight Factors Continued High-Speed Volume
Shenzhou Cell (688520): Reorganization of the Eight Factors, Rapid Release, Focus on the Progress of CD20 Health Insurance Negotiations
No Data